NCT07215494View on ClinicalTrials.gov

A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions
Light Chain (AL) AmyloidosisMRD
Interventions
DRUG

First-Line Dara-BorCyD Treatment

First-Line Dara-BorCyD Treatment Achieves CR, but ASCT is Recommended for MRD-Positive Patients

Trial Locations (1)

100034

Peking University First Hospital, Beijing

All Listed Sponsors
collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

Beijing Anzhen Hospital

OTHER

lead

Peking University First Hospital

OTHER

NCT07215494 - A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis | Biotech Hunter | Biotech Hunter